C4 Therapeutics, Inc. (CCCC) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 10 recommend buying, 3 recommend holding, and 1 recommend selling.
The analyst consensus price target for CCCC is $7.00, representing a +153.6% upside from the current price of $2.76. Price targets range from a low of $7.00 to a high of $7.00.
